Clinical Trials
52 trialsTrastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
Daiichi Sankyo
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
AstraZeneca
PAROLA
Institut Claudius Regaud
TROPION-Lung12
AstraZeneca
iCCaRE
University of Ilorin Teaching Hospital
Spotlight
Astellas Pharma Inc
LUCERNA
Astellas Pharma Inc
GLOW
Astellas Pharma Inc
TRIPLE-SWITCH
Canadian Cancer Trials Group
AcceleRET-Lung
Hoffmann-La Roche
Efficacy and Safety of VasoClip® vs. WeckClip® for Robotic Urologic Surgery
Incheon St.Mary's Hospital
A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
Akeso
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
Maia Biotechnology
PREACT
Shanghai Cancer Hospital, China
NACRE-2
UNICANCER
PEACE2
UNICANCER
INTEGRATEIIb
Australasian Gastro-Intestinal Trials Group
PCS-XII
Charles LeMoyne Hospital
OPTIMA
Imunon
ESOPEC
University Hospital Schleswig-Holstein
M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
FutureGen Biopharmaceutical (Beijing) Co., Ltd
CanStem111P
Sumitomo Pharma America, Inc.
Perioperative FLOT vs Adjuvant XELOX for CA Stomach
Chinese University of Hong Kong
apact
Celgene
Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer
NuCana plc
METHADOPT
Ottawa Hospital Research Institute
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
NSABP Foundation Inc
INTEGRATEIIa
Australasian Gastro-Intestinal Trials Group
ALTA-1L
Takeda
Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer
Ruijin Hospital
CIPHER
University of Texas Southwestern Medical Center
Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix
M.D. Anderson Cancer Center
Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma
Eli Lilly and Company
RAINBOW
Eli Lilly and Company
PANCREADOGREL
Assistance Publique - HĂ´pitaux de Paris
Laparoscopic Approach to Cancer of the Endometrium
Queensland Centre for Gynaecological Cancer
BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)
Boehringer Ingelheim
ICWIP
Betta Pharmaceuticals Co., Ltd.
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
Boehringer Ingelheim
AVAGAST
Genentech, Inc.
ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures
Sanofi
Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma
Takeda
Net-Pac
CHIR-Net
NEOPAC
Institut Paoli-Calmettes
Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
Abbott
Evaluation of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical Cancer
UNICANCER
Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer
Pfizer
Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma
Novartis
First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker
National Cancer Center, Korea